[nle27]ghrh-(1-29)-nh2
[nle27]ghrh-(1-29)-nh2 has been studied in 1 paper since 1997: 1 trial in people. The newest paper, May 1, 1997: “Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women”.
1 paper studies it6 findingsUpdated
See all 1 papers on [nle27]ghrh-(1-29)-nh2
At a glance
The findings reach people, from one lab or study. 1 lab in 1 country.
“Compared with placebo, GHRH analog induced a significant increase in 12-h integrated nocturnal GH levels in women (P < 0.01) and men (P < 0.05).”
None of its findings points the other way.
- 1 lab in 1 country
- Funders: National Center for Advancing Translational Sciences and 3 more
- Human trial1
Studies in people
1 study gave [nle27]ghrh-(1-29)-nh2 to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Increases skin thickness up: Increases lean body mass | Randomized trial16 weeks | 9 peopleBoth55–71 yearsMidlife adults; Older adults | The Journal of clinical endocrinology and metabolism, May 1, 1997 |
What did studies of [nle27]ghrh-(1-29)-nh2 find?
6Studies of [nle27]ghrh-(1-29)-nh2 measured 6 outcomes, among them hyperlipidemia, general well-being and insulin sensitivity.
Hyperlipidemia
upin humans1
1 study
Hyperlipidemia
upin humans1
[nle27]ghrh-(1-29)-nh2 induces hyperlipidemia in humans.
“The only adverse side-effect was transient hyperlipidemia, which resolved by the end of the study.”
Human trial10 microg/kg nightlyresolved by the end of the study
The Journal of clinical endocrinology and metabolism
General well-being
upin humans1
1 study
General well-being
upin humans1
[nle27]ghrh-(1-29)-nh2 improves general well-being in humans.
“a significant improvement in general well-being (P < 0.05) and libido (P < 0.01) in men, but not in women”
Human trial10 microg/kg nightly16 weeksmalesn = 9
The Journal of clinical endocrinology and metabolism
Insulin sensitivity
upin humans1
1 study
Insulin sensitivity
upin humans1
[nle27]ghrh-(1-29)-nh2 increases insulin sensitivity in humans.
“a significant increase in insulin sensitivity occurred in men (P < 0.05), but not in women.”
Human trial10 microg/kg nightly16 weeksmalesn = 9
The Journal of clinical endocrinology and metabolism
Lean body mass
upin humans1
1 study
Lean body mass
upin humans1
[nle27]ghrh-(1-29)-nh2 increases lean body mass in humans.
“increased lean body mass in men only (P < 0.05)”
Human trial10 microg/kg nightly16 weeksmalesn = 9
The Journal of clinical endocrinology and metabolism
Skin thickness
upin humans1
1 study
Skin thickness
upin humans1
[nle27]ghrh-(1-29)-nh2 increases skin thickness in humans.
“GHRH analog treatment resulted in a significant increase in skin thickness (P < 0.05) in both genders”
Human trialskin10 microg/kg nightly16 weeks
The Journal of clinical endocrinology and metabolism
Nocturnal GH
upin humans1
1 study
Nocturnal GH
upin humans1
[nle27]ghrh-(1-29)-nh2 increases nocturnal GH in humans (compared with placebo).
“Compared with placebo, GHRH analog induced a significant increase in 12-h integrated nocturnal GH levels in women (P < 0.01) and men (P < 0.05).”
Human trialcompared with placebo10 microg/kg nightly16 weeks
The Journal of clinical endocrinology and metabolism